An evidence-based guide to every clinically significant drug interaction with testosterone cypionate, including mechanisms, severity grades, and management strategies backed by PubMed and FDA sources.
A comparison of compounded and branded testosterone cypionate covering pharmacokinetics, FDA oversight, cost, clinical trial evidence, and how to choose the right formulation for male hypogonadism treatment.
A guide to discontinuing testosterone cypionate, covering HPTA suppression, tapering protocols, post-cycle recovery, and what to expect during the transition off TRT.
A clinician-level guide to safely resuming testosterone cypionate injections after acute illness, covering timing, dose adjustments, lab monitoring, and the evidence behind restart decisions.
A clinician-level guide to switching testosterone cypionate to or from other androgen formulations, covering mechanism, pharmacokinetics, dose conversion, washout periods, and monitoring protocols with PubMed-cited evidence.
A week-by-week guide to testosterone cypionate's first month: what changes when, what the clinical evidence says, and how to manage side effects safely.
Testosterone cypionate forms an IM depot, releases free testosterone via esterases, binds AR, converts to DHT or estradiol, and suppresses the HPG axis.
Testosterone became a Schedule III controlled substance in 1990. See testosterone cypionate's 1951 synthesis, 1979 FDA approval, and dosing history.